| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-10-01 |
复牌提示：
2020-09-30 19:54:56 停牌，复牌日期 2020-10-02 00:00:01
|
| 2020-08-10 |
详情>>
股本变动：
变动后总股本11884.80万股
|
| 2020-08-10 |
财报披露：
美东时间 2020-08-10 盘前发布财报
|
| 2020-08-10 |
详情>>
业绩披露：
2020年中报每股收益-0.82美元,归母净利润-9658.7万美元,同比去年增长39.18%
|
| 2020-05-07 |
详情>>
业绩披露：
2020年一季报每股收益-0.34美元,归母净利润-3955.5万美元,同比去年增长11.79%
|
| 2020-04-24 |
股东大会：
将于2020-06-23召开股东大会
会议内容 ▼▲
- 1.to elect Bruce L. Downey and Georges Gemayel to our board of directors to serve as Class I directors, each for a term of three years;
2.to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.to approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, which, among other things, increases the number of shares authorized for issuance by 7,000,000 shares.
|
| 2020-02-27 |
详情>>
业绩披露：
2017年年报每股收益-1.2美元,归母净利润-8809.6万美元,同比去年增长-319.44%
|
| 2020-02-27 |
详情>>
业绩披露：
2019年年报每股收益-2.92美元,归母净利润-2.9亿美元,同比去年增长-64.75%
|
| 2019-11-04 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-2.06美元,归母净利润-2.03亿美元,同比去年增长-21.18%
|
| 2019-08-07 |
详情>>
业绩披露：
2019年中报每股收益-1.61美元,归母净利润-1.59亿美元,同比去年增长-35.14%
|
| 2019-05-03 |
详情>>
业绩披露：
2018年一季报每股收益-0.63美元,归母净利润-4763.1万美元,同比去年增长-49.98%
|
| 2019-05-03 |
详情>>
业绩披露：
2019年一季报每股收益-0.46美元,归母净利润-4484.3万美元,同比去年增长5.85%
|
| 2019-04-26 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.to elect Steven C. Gilman, Thomas P. Koestler and Elizabeth Stoner to our board of directors to serve as Class III directors, each for a term of three years;
2.to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.to approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, which, among other things, increases the number of shares authorized for issuance by 4,000,000 shares.
|
| 2019-02-22 |
详情>>
业绩披露：
2018年年报每股收益-2.26美元,归母净利润-1.76亿美元,同比去年增长-99.85%
|
| 2019-01-03 |
股东大会：
将于2019-01-30召开股东大会
会议内容 ▼▲
- 1.the amendment of the Company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 100,000,000 to 200,000,000;
2.the approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1.
|
| 2018-11-07 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-2.2美元,归母净利润-1.68亿美元,同比去年增长-64.76%
|
| 2018-08-09 |
详情>>
业绩披露：
2018年中报每股收益-1.55美元,归母净利润-1.18亿美元,同比去年增长-71.14%
|
| 2018-07-09 |
详情>>
内部人交易：
Stoner Elizabeth共交易2笔
|
| 2018-04-27 |
股东大会：
将于2018-06-20召开股东大会
会议内容 ▼▲
- 1.to elect Jose-Carlos Gutiérrez-Ramos, James R. Sulat, and Craig A. Wheeler to our board of directors to serve as Class II directors, each for a term of three years;
2.to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.to approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, which, among other things, increases the number of shares authorized for issuance by 1,000,000 shares.
|
| 2017-04-27 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1.to elect Bruce L. Downey, Corey N. Fishman, and Georges Gemayel to our board of directors to serve as Class I directors, each for a term of three years;
2.to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.to approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers;
5.to approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, which, among other things, increases the number of shares authorized for issuance by 4,300,000 shares;
6.to approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan, which increases the number of shares authorized for issuance by 1,400,000 shares.
|
| 2016-04-27 |
股东大会：
将于2016-06-22召开股东大会
会议内容 ▼▲
- 1.to elect Thomas P. Koestler and Elizabeth Stoner to our board of directors to serve as Class III directors, each for a term of three years;
2.to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2016;
3.to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.to approve the Amendment and Restatement of the 2013 Incentive Award Plan that, among other things, increases the number of shares authorized for issuance by 4,250,000 shares.
|
| 2015-04-24 |
股东大会：
将于2015-06-09召开股东大会
会议内容 ▼▲
- 1.to elect John K. Clarke, James R. Sulat, and Craig A. Wheeler to our board of directors to serve as Class II directors, each for a term of three years;
2.to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2015;
3.to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.to approve the Amendment and Restatement of the 2013 Incentive Award Plan that, among other things, increases the number of shares authorized for issuance by 2,550,000 shares.
|
| 2014-04-22 |
股东大会：
将于2014-06-11召开股东大会
会议内容 ▼▲
- 1. to elect Bruce L. Downey, Marsha H. Fanucci, and Peter Barton Hutt to our board of directors to serve as Class I directors, each for a term of three years;
2. to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2014;
3. to approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4. to approve the Amendment and Restatement of the Employee Stock Purchase Plan;
5. to approve the Amendment and Restatement of the 2013 Incentive Award Plan that increases the number of shares authorized for issuance by 1,800,000 shares.
|
| 2013-04-22 |
股东大会：
将于2013-06-11召开股东大会
会议内容 ▼▲
- 1. to elect three members to our board of directors to serve as Class III directors, each for a term of three years;
2. to ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2013;
3. to approve, on an advisory basis, the compensation of our named executive officers;
4. to approve the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan.
|